1677 related articles for article (PubMed ID: 17895328)
21. Cost and utilization outcomes of opioid-dependence treatments.
Baser O; Chalk M; Fiellin DA; Gastfriend DR
Am J Manag Care; 2011 Jun; 17 Suppl 8():S235-48. PubMed ID: 21761950
[TBL] [Abstract][Full Text] [Related]
22. Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia.
Berger A; Edelsberg J; Kallich J; Oster G
Clin Ther; 2008 Jan; 30(1):206-18. PubMed ID: 18343258
[TBL] [Abstract][Full Text] [Related]
23. An economic evaluation of erythropoiesis-stimulating agents in CKD.
Clement FM; Klarenbach S; Tonelli M; Wiebe N; Hemmelgarn B; Manns BJ
Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621
[TBL] [Abstract][Full Text] [Related]
24. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
[TBL] [Abstract][Full Text] [Related]
25. Erythropoiesis-stimulating agent use for anemia induced by interferon-ribavirin treatment in patients with hepatitis C virus infection is not associated with increased rates of cardiovascular disease, thrombosis, malignancy, or death.
Costiniuk CT; Camacho F; Cooper CL
Clin Infect Dis; 2008 Jul; 47(2):198-202. PubMed ID: 18532889
[TBL] [Abstract][Full Text] [Related]
26. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.
Pelletier EM; Shim B; Goodman S; Amonkar MM
Breast Cancer Res Treat; 2008 Mar; 108(2):297-305. PubMed ID: 17577662
[TBL] [Abstract][Full Text] [Related]
27. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
[TBL] [Abstract][Full Text] [Related]
28. Cost and utilization of COPD and asthma among insured adults in the US.
Blanchette CM; Broder M; Ory C; Chang E; Akazawa M; Dalal AA
Curr Med Res Opin; 2009 Jun; 25(6):1385-92. PubMed ID: 19419342
[TBL] [Abstract][Full Text] [Related]
29. Treatment of anemia with erythropoietin-stimulating agents in kidney transplant recipients and chronic kidney disease-another drawback of immunosuppression?
Malyszko J; Glowinska I; Mysliwiec M
Transplant Proc; 2012 Dec; 44(10):3013-6. PubMed ID: 23195016
[TBL] [Abstract][Full Text] [Related]
30. Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.
Vekeman F; McKenzie RS; Bookhart BK; Laliberté F; Duh MS; Tak Piech C; Lefebvre P
J Med Econ; 2009 Mar; 12(1):1-8. PubMed ID: 19450059
[TBL] [Abstract][Full Text] [Related]
31. Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective.
Gauthier-Loiselle M; Michalopoulos SN; Cloutier M; Serra E; Bungay R; Szabo E; Guérin A
J Manag Care Spec Pharm; 2021 Dec; 27(12):1703-1713. PubMed ID: 34818094
[No Abstract] [Full Text] [Related]
32. Impact of initiation timing of SSRI or SNRI on depressed adolescent healthcare utilization and costs.
Yu AP; Ben-Hamadi R; Wu EQ; Kaltenboeck A; Bergman R; Xie J; Blum S; Erder MH
J Med Econ; 2011; 14(4):508-15. PubMed ID: 21692605
[TBL] [Abstract][Full Text] [Related]
33. Erythropoietin-induced treatment costs in patients suffering from renal anemia - a comparison between biosimilar and originator drugs.
Hörbrand F; Rottenkolber D; Fischaleck J; Hasford J
Gesundheitswesen; 2014 Nov; 76(11):e79-84. PubMed ID: 24493578
[TBL] [Abstract][Full Text] [Related]
34. Undertreatment of anemia in patients with chronic kidney disease in the United States: analysis of national outpatient survey data.
Rasu RS; Manley HJ; Crawford T; Balkrishnan R
Clin Ther; 2007 Jul; 29(7):1524-34. PubMed ID: 17825703
[TBL] [Abstract][Full Text] [Related]
35. Healthcare utilization associated with dyspepsia in patients with arthritis.
Zhao SZ; Arguelles LM; Dedhiya SD; Morgan DG
Am J Manag Care; 1999 Oct; 5(10):1285-95. PubMed ID: 10622994
[TBL] [Abstract][Full Text] [Related]
36. Incremental cost effectiveness of pharmacist-managed erythropoiesis-stimulating agent clinics for non-dialysis-dependent chronic kidney disease patients.
Aspinall SL; Smith KJ; Good CB; Zhao X; Stone RA; Tonnu-Mihara IQ; Cunningham FE
Appl Health Econ Health Policy; 2013 Dec; 11(6):653-60. PubMed ID: 24092553
[TBL] [Abstract][Full Text] [Related]
37. Economic evaluation of erythropoiesis-stimulating agents for anemia related to cancer.
Klarenbach S; Manns B; Reiman T; Reaume MN; Lee H; Lloyd A; Wiebe N; Hemmelgarn B; Tonelli M
Cancer; 2010 Jul; 116(13):3224-32. PubMed ID: 20564645
[TBL] [Abstract][Full Text] [Related]
38. Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity.
Barsky AJ; Orav EJ; Bates DW
Arch Gen Psychiatry; 2005 Aug; 62(8):903-10. PubMed ID: 16061768
[TBL] [Abstract][Full Text] [Related]
39. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
[TBL] [Abstract][Full Text] [Related]
40. Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients.
Schumock GT; Andress DL; Marx SE; Sterz R; Joyce AT; Kalantar-Zadeh K
Nephron Clin Pract; 2009; 113(1):c54-61. PubMed ID: 19590235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
